Nurix Therapeutics, Inc.
NASDAQ:NRIXBiotechnology
+$0.15 today
- Market cap
- $1.54B
- Beta
- 1.87
- P/E (TTM)
- -6.4
- EPS (TTM)
- -$2.68
Volume 2.79M
Average 1.74M
Returns on capital
Nurix Therapeutics, Inc. management
Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.
Return Metrics
ROE, ROIC & ROA over time
ROE
-49.1%
avg -25.4%
ROIC
-47.3%
avg -48.8%
ROA
-38.4%
avg -32.1%
Analysis
ROA is currently the strongest return metric at -38.4% versus its period average of -32.1%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Leadership
Who runs the company?
Review the executive team, tenure, compensation, and ownership.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|
Arthur T. Sands | Chief Executive Officer, President & Director | USD 1.21M | 64 | 562.50K | 0.65% |
Gwenn Hansen | Chief Scientific Officer | USD 866.28K | 55 | 57.95K | 0.07% |
Johannes Van Houte | Chief Financial Officer | USD 848.25K | 59 | — | — |
Christine Ring | Chief Legal Officer, Secretary & Chief Compliance Officer | USD 815.09K | 61 | 4.41K | <0.01% |
Arthur Weiss | Founder & Member of Scientific Advisory Board | — | — | — | — |
John Kuriyan | Founder & Member of Scientific Advisory Board | — | — | — | — |
Jason Kantor | Chief Business Officer | — | — | — | — |
Pasit Phiasivongsa | Chief Technical Officer | — | — | — | — |
Wesley Burwell | Chief Human Resources Officer | — | — | — | — |
Rita Kwong | Senior Accounting Manager | — | — | — | — |
Compensation is shown in the reported currency; data updated Nov 7, 2026.
Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Nov 3, 2026.
Insider trading
Are insiders buying or selling?
Follow recent insider purchases and sales reported on Form 4.
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
0
$0.00
Sells
48
$5.84M
Net Transaction Value
−$5.84M
Net selling
Most Active
Ring Christine
24 transactions
Transactions sorted by date, descending.
| Type | |||
|---|---|---|---|
| Nov 4, 26Nov 4, 2026 | van Houte Hans Direct | Sell | $23.8K$23,800.44 |
| Nov 4, 26Nov 4, 2026 | van Houte Hans Direct | Sell | $50.8K$50,761.92 |
| Nov 3, 26Nov 3, 2026 | Ring Christine Direct | Sell | $157.9K$157,916.52 |
| Nov 2, 26Nov 2, 2026 | Ring Christine Direct | Sell | $28.8K$28,770.01 |
| Nov 2, 26Nov 2, 2026 | Hansen Gwenn Direct | Sell | $38.9K$38,913.60 |
| Nov 2, 26Nov 2, 2026 | Ring Christine Direct | Sell | $245.2K$245,217.36 |
| Oct 30, 26Oct 30, 2026 | Ring Christine Direct | Sell | $104K$103,986.40 |
| Oct 30, 26Oct 30, 2026 | Hansen Gwenn Direct | Sell | $104K$103,986.40 |
| Oct 30, 26Oct 30, 2026 | van Houte Hans Direct | Sell | $74.5K$74,474.97 |
| Oct 15, 26Oct 15, 2026 | Hansen Gwenn Direct | Sell | $36.3K$36,300.00 |
1–10 of 48
Summary
Insiders reported 0 buys worth $0.00 and 48 sells worth $5.84M over the last 12 months. That adds up to net selling of $5.84M. Ring Christine was the most active insider with 24 transactions.
Growth analysis
Is management growing the business?
Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | +29.5% | +31.3% (5yr)2 analysts |
| Net Income | N/A | N/A | N/A | N/A2 analysts |
| EBIT | N/A | N/A | N/A | N/A2 analysts |
Analysis
Recent growth has been strongest in Revenue at +29.5% over three years. Forward estimates point to Revenue at +31.3% (5yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Who does Nurix Therapeutics, Inc. compete with?
Open similar companies to compare how their management teams allocate capital.
Questions
Management questions
Common questions about NRIX's management, answered from reported figures.
Who manages NRIX?
Nurix Therapeutics, Inc. (NRIX) lists 10 active executives. The top listed executive is Arthur Weiss, Founder & Member of Scientific Advisory Board.
Are NRIX insiders buying or selling?
Recent insider activity shows net buying of $12.47M.
Continue the stock analysis
Jump to another research area for this company.